Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01EYR
|
|||
| Former ID |
DIB015093
|
|||
| Drug Name |
ImmunoVEX-timelan
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1/2 | [1] | |
| Company |
BioVex
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.